<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351204</url>
  </required_header>
  <id_info>
    <org_study_id>N18BREL</org_study_id>
    <secondary_id>NL 65953.031.18</secondary_id>
    <nct_id>NCT04351204</nct_id>
  </id_info>
  <brief_title>The MR-Linac Technical Feasibility Protocol</brief_title>
  <acronym>UMBRELLA-II</acronym>
  <official_title>The MR-Linac Technical Feasibility Protocol For Development of MR-guided Adaptive RadiationTherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elekta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation therapy is predominantly based on a Computed Tomography (CT) scan obtained during
      the treatment planning phase. During the course of radiotherapy, however, both the tumor and
      organs at risk (OAR) are variable in position, shape and size between fractions, and during
      beam delivery within one treatment fraction. Around the clinical target volume (CTV) a safety
      margin (Planning Target Volume, PTV) is created to account for these geometric uncertainties
      to ensure that the tumor receives the prescribed dose.

      Direct integration of imaging at the linear accelerator enables daily monitoring of patient
      positioning, tumor position, and alterations in patient anatomy. Image guided radiotherapy
      (IGRT) enables the detection and immediate correction of such deviations and increases the
      precision of delivery.

      Adaptive radiotherapy has become an important strategy for serially modifying dose
      distributions in a manner that can substantially reduce OAR dose and subsequent toxicity,
      while maintaining adequate target coverage. Current adaptive protocols rely upon a standard
      CT-based workflow and (cone-beam) CT-based image guidance.

      Magnetic Resonance Imaging (MRI) has superior soft-tissue contrast over CT and seems a very
      promising modality to integrate in the radiation treatment process, facilitating better
      visualization of the tumor and OAR during treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed protocol aims to determine feasibility of multiple new techniques and software
      for MR-guided adaptive radiation therapy. For each proposed technique feasibility has to be
      determined individually. A secondary aim is to prospectively collect data from cohorts of
      patients treated at the MRL and report on acute toxicity.

      By including multiple parallel cohorts, the protocol will accelerate the technical
      development of MR-guided adaptive radiotherapy and the evidence-based introduction of the MRL
      into clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>technical feasibility</measure>
    <time_frame>4 years</time_frame>
    <description>Feasibility of the technical procedure is demonstrated if the technique is successfully applied in 9 out of 10 consecutive patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Tumors at All Sites Which Will Receive Radiotherapy</condition>
  <arm_group>
    <arm_group_label>MRL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>radiotherapy on MR linac</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>multiple new techniques and software for MR-guided adaptive radiation therapy.</description>
    <arm_group_label>MRL</arm_group_label>
    <other_name>MR Linac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient, age ≥ 18 years, treated with radiation therapy on the MRL.

          -  WHO performance 0-2.

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Contra-indications for an MRI examination.

          -  Patient is pregnant.

          -  Claustrophobia.

          -  Patients &gt;140 kg and/or a body width &gt; 60 cm.

          -  Patients with any other clinically significant medical condition which, in the opinion
             of the treating physician, makes it undesirable for the patient to participate in the
             study or which could jeopardize compliance with study requirements or severe
             psychiatric illness/social situation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlies Nowee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlies Nowee, MD, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>m.nowee@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uulke vd Heide, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>u.vd.heide@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlies Nowee, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>m.nowee@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Uulke vd Heide, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>u.vd.heide@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marlies Nowee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Bujold A, Craig T, Jaffray D, Dawson LA. Image-guided radiotherapy: has it influenced patient outcomes? Semin Radiat Oncol. 2012 Jan;22(1):50-61. doi: 10.1016/j.semradonc.2011.09.001. Review.</citation>
    <PMID>22177878</PMID>
  </results_reference>
  <results_reference>
    <citation>De Los Santos J, Popple R, Agazaryan N, Bayouth JE, Bissonnette JP, Bucci MK, Dieterich S, Dong L, Forster KM, Indelicato D, Langen K, Lehmann J, Mayr N, Parsai I, Salter W, Tomblyn M, Yuh WT, Chetty IJ. Image guided radiation therapy (IGRT) technologies for radiation therapy localization and delivery. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):33-45. doi: 10.1016/j.ijrobp.2013.02.021. Epub 2013 May 7.</citation>
    <PMID>23664076</PMID>
  </results_reference>
  <results_reference>
    <citation>Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, Green O, Wooten O, Li HH, Hu Y, Rodriguez V, Olsen L, Robinson C, Michalski J, Mutic S, Olsen J. Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):394-403. doi: 10.1016/j.ijrobp.2015.10.015. Epub 2015 Oct 17. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):243.</citation>
    <PMID>26678659</PMID>
  </results_reference>
  <results_reference>
    <citation>McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A; MR-Linac consortium. MRI-guided prostate adaptive radiotherapy - A systematic review. Radiother Oncol. 2016 Jun;119(3):371-80. doi: 10.1016/j.radonc.2016.04.014. Epub 2016 May 6. Review.</citation>
    <PMID>27162159</PMID>
  </results_reference>
  <results_reference>
    <citation>Vestergaard A, Hafeez S, Muren LP, Nill S, Høyer M, Hansen VN, Grønborg C, Pedersen EM, Petersen JB, Huddart R, Oelfke U. The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. Radiother Oncol. 2016 Jan;118(1):154-9. doi: 10.1016/j.radonc.2015.11.003. Epub 2015 Nov 26.</citation>
    <PMID>26631646</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>MR Linac</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

